Skip to Content

PHENYLEPHRINE 10 MG/ML INJECTION

Active substance(s): PHENYLEPHRINE HYDROCHLORIDE

View full screen / Print PDF » Download PDF ⇩
Transcript
102961/LF/2

22595232
FOR THE INFORMATION OF THE MEDICAL PROFESSION.

PRODUCT NAME:

Phenylephrine 10 mg/ml Injection
Phenylephrine hydrochloride

PIP CODE:
COMPONENT:
SIZE:
MARKET:
COMMODITY NO.:
PRODUCT SITE:
SCALE:
COLOURS:
DATE:
FONT SIZE:
VERSION NO:
AMENDED BY:
PROJECT:

Phenylephrine Injection is a sterile solution of Phenylephrine Hydrochloride in purified
water.
Phenylephrine is a sympathomimetic agent with mainly direct effects on adrenergic
receptors. It has predominantly alpha-adrenergic activity and is without significant
stimulating effects on the central nervous system at usual doses. After injection, it
produces peripheral vasoconstriction and an increase in arterial pressure. It also produces
reflex bradycardia.
Indications
Phenylephrine Injection is indicated in adults and children to treat hypotensive states, for
example circulatory failure during spinal anaesthesia, or drug induced hypotension.
Contraindications, Warnings, etc.
Phenylephrine Injection is contraindicated in the presence of severe hypertension and
hyperthyroidism. It should not be given to patients being treated with monoamine oxidase
inhibitors, nor within two weeks of stopping such treatment. Extreme caution is required
in patients with pre-existing cardiovascular disease, such as ischaemic heart disease,
arrhythmias and occlusive vascular disease. Anginal pain may be precipitated in patients
with angina pectoris. Care is also required in patients with diabetes mellitus or closed
angle glaucoma.
Interactions
Phenylephrine may interact with cyclopropane, halothane and other halogenated
inhalational anaesthetics to induce ventricular fibrillation. There may be an increased risk
of arrhythmias with concomitant use of cardiac glycosides, quinidine and tricyclic
antidepressants. Phenylephrine, by increasing the blood pressure, may reverse the effect
of many antihypertensives. Interactions of phenylephrine with alpha receptor
agonists/antagonists and beta receptor blocking drugs may be complex. Caution should
be applied when administering atomoxetine concurrently, as there is potential for
synergistic pharmacological effects. Severe hypertension may occur following the use of
phenylephrine and atropine or other antimuscarinics. The pressor effects of phenylephrine
may be slightly reduced by lithium carbonate. The effects of phenylephrine may be
potentiated by the use of monoamine oxidase inhibitors or reversible inhibitors of
monoamine oxidase.
Use in Pregnancy and Lactation
The safety of phenylephrine during pregnancy has not been established. Due to the
vasoconstrictive properties of phenylephrine, the product should be used with caution in
patients with a history of pre-eclampsia. Administration in late pregnancy or labour may
cause foetal hypoxia and bradycardia.
Breast-feeding
The safety of phenylephrine during lactation has not been established. Excretion of
phenylephrine in breast milk appears to be minimal.
Dosage and Administration
Adults:
By subcutaneous or intramuscular injection: 2 to 5 mg, with further doses of 1 to 10 mg if
necessary, according to response.
By slow intravenous injection: 100 to 500 micrograms as a 0.1% solution, repeated as
necessary after at least 15 minutes.
By intravenous infusion: 10 mg in 500 ml of glucose 5% or sodium chloride 0.9%
infused initially at a rate of up to 180 micrograms per minute. This should be reduced to
30 – 60 micrograms per minute according to response.
Elderly: No special dosage reduction necessary.
Paediatric population: 100 micrograms per kilogram of body weight subcutaneously or
intramuscularly.
Adverse Effects
• Immune system disorders
• Hypersensitivity
• Metabolism and nutrition disorders
• Metabolic disorders
• Psychiatric disorders
• Nervousness, insomnia
• Nervous system disorders
• Headache, cerebral haemorrhage, paraesthesia
• Eye disorders
• Mydriasis, angle-closure glaucoma
• Cardiac disorders
• Pulmonary oedema, bradycardia, tachycardia, arrhythmia, angina pectoris,
palpitations, cardiac arrest
• Vascular disorders
• Hypotension, dizziness, syncope, flushing
• Respiratory, thoracic and mediastinal disorders
• Dyspnoea
• Gastrointestinal disorders
• Vomiting, salivary hypersecretion
• Renal and urinary disorders
• Dysuria, urinary retention
• General disorders and administration site conditions
• Extravasation, infusion site necrosis, hyperhidrosis
• Investigations
• Increased blood pressure, abnormal blood glucose
• Phenylephrine is without significant stimulating effects on the central nervous system
at usual doses.
Treatment of Overdosage
Symptoms of overdosage include headache, vomiting, hypertension and reflex
bradycardia and other cardiac arrhythmias. In severe cases confusion, hallucinations
and seizures may occur. Treatment should consist of symptomatic and supportive
measures. Hypertensive effects may be treated with an alpha-blocker such as
phentolamine, 5 to 60 mg given intravenously over 10 to 30 minutes, repeated as
necessary.
Additional information
Phenylephrine acts within 10 to 15 minutes following subcutaneous or intramuscular
injection. Subcutaneous injections are effective for up to around 1 hour and intramuscular
injections for up to around 2 hours. Intravenous injections are effective for up to around
20 minutes. Phenylephrine is metabolised in the liver by monoamine oxidase.
PL 20072/0226
Further information is available on request.
Amdipharm UK Limited,
Capital House,
85 King William Street,
London EC4N 7BL, UK
This leaflet was last revised: March 2014.

Phenylepherine Inj.
10 mg per ml
102961/LF/2
Leaflet
148 x 600 mm
Great Britain
22595232
TBC
100%
Black & Cutter
19/03/2014
12 pt
1
AMCo
CAC

REGULATORY AUTHORITY
APPROVAL CONFIRMATION
Confirmation that this artwork has been approved by
the appropriate market authority (if applicable, e.g.
MHRA, IMB, etc and that Amdipharm have license
approval to distribute this component for sale in the
relevent market.
Accept Artwork ................................................................
Reject Artwork .................................................................
Signature ..........................................................................
Name ................................................................................
Date ...................................................................................

PAGE 1 OF 2

102961/LF/2

22595232
Package leaflet: Information for the patient

PRODUCT NAME:

Phenylephrine 10 mg/ml Injection
Phenylephrine hydrochloride

PIP CODE:
COMPONENT:
SIZE:
MARKET:
COMMODITY NO.:
PRODUCT SITE:
SCALE:
COLOURS:
DATE:
FONT SIZE:
VERSION NO:
AMENDED BY:
PROJECT:

Read all of this leaflet carefully before you start using this medicine because it contains
important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may
harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
1. What Phenylephrine Injection is and what it is used for
2. What you need to know before you use Phenylephrine Injection
3. How to use Phenylephrine Injection
4. Possible side effects
5. How to store Phenylephrine Injection
6. Contents of the pack and other information
1. WHAT PHENYLEPHRINE INJECTION IS AND WHAT IT IS USED FOR
The name of your medicine is Phenylephrine 10 mg/ml Injection (called Phenylephrine
Injection in this leaflet). Its active ingredient is phenylephrine hydrochloride.
Each 1 ml ampoule contains 10 mg of Phenylephrine Hydrochloride in purified water,
Phenylephrine belongs to a group of medicines called anti-hypotensive drugs.
Phenylephrine Injection is used in adults and children to relieve low blood pressure which
may occur during an operation or after an injury.
2. WHAT YOU NEED TO KNOW BEFORE YOU USE PHENYLEPHRINE INJECTION
Do not use Phenylephrine Injection:
- If you are allergic to phenylephrine hydrochloride or any of the other ingredients of
this medicine (listed in section 6)
- You are taking a group of medicines called monoamine oxidase inhibitors (MAOIs) or
have stopped taking them within the last 14 days
- You have high blood pressure, or an overactive thyroid (hyperthyroidism).
Warnings and precautions
Talk to your doctor or pharmacist before using Phenylephrine Injection
- If you have heart conditions such as the following: ischaemic heart disease,
arrhythmia, angina pectoris, occlusive vascular disease, high blood pressure or
aneurysms
- If you have diabetes mellitus, diabetic autonomic neuropathy (a complication of
diabetes mellitus) or closed angle glaucoma
- You have inflammation of the liver (hepatitis) or pancreas (pancreatitis)
Other medicines and Phenylephrine Injection
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other
medicines.
Tell your doctor if you have taken antidepressants (either currently or within the last
14 days).
Tell your doctor if you have taken tablets for heart problems or high blood pressure.
Phenylephrine may interact with some drugs used as general anaesthetics, but your
doctor will be fully prepared to deal with this should it occur.
Phenylephrine may interact with a drug used to treat attention-deficit hyperactivity
disorder (ADHD) called atomoxetine.
Phenylephrine may also interact with drugs called antimuscarinics (e.g. atropine.)
Lithium (a drug used for depression or aggression) may affect how phenylephrine works.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a
baby, ask your doctor or pharmacist for advice before taking this medicine. The safety of
phenylephrine during pregnancy and breast-feeding has not been established.
Driving and using machines
Phenylephrine Injection should not affect your ability to drive. As with all medicines, if you
feel unwell you must speak to your doctor or nurse before driving or operating machinery.
Phenylephrine Injection contains sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e.
essentially sodium-free.
3. HOW TO USE PHENYLEPHRINE INJECTION
As Phenylephrine Injection is given by injection, the doctor will administer it to you.
Adults: The dose depends on the way it is given, e.g. if injected into a muscle or just under
the skin, the recommended dose is 2 to 5 mg. If injected directly into a vein, this is carried
out slowly using a more dilute solution of up to 10 mg.
Use in children and adolescents
The recommended dose is 100 micrograms per kilogram of body weight, injected into a
muscle or just under the skin.
If you use more Phenylephrine Injection than you should
It is unlikely that you will be given too much Phenylephrine Injection; however should an
overdose occur the doctor will treat any symptoms that follow. Symptoms of overdose
include headache, feeling sick, high blood pressure, a fast or irregular heart beat,
confusion, hallucinations and fits.
4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets
them.
Side effects of Phenylephrine Injection may include:
• Allergic reaction symptoms such as itching/ rash, swelling of your face, lips or throat
or difficulty in breathing/ wheeziness
• Fluid on the lungs and/or bleeding in the brain
• A drop in blood pressure may occur with dizziness, fainting and flushing
• Changes in heart rate and rhythm
• Anginal pain
• Heart block
• Difficulty in passing urine
• Shortness of breath
• Enlarged pupils, which may make your vision blurry
• Headache
• Feeling sick
• Tingling and coolness of the skin
• Sweating
• An increase in saliva
• A feeling of fullness in the head
• Changes in blood sugar levels
• Occasional skin reactions
• Nervousness
• Difficulty sleeping
• Angle closure glaucoma (when pressure rises quickly inside the eye).
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible
side effects not listed in this leaflet. You can also report side effects directly via the Yellow
Card Scheme, website: www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this
medicine.
5.

HOW TO STORE PHENYLEPHRINE INJECTION

KEEP THIS MEDICINE OUT OF THE SIGHT AND REACH OF CHILDREN
Phenylephrine Injection will be stored either in a refrigerator or at room temperature
(2°C – 25°C), protected from light, until it is given to you. The doctor or nurse will check
that the expiry date on the label has not passed before you are given the injection.
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Phenylephrine Injection contains
Each 1 ml ampoule contains 10 mg of the active substance phenylephrine hydrochloride.
The other ingredients are sodium hydroxide solution, hydrochloric acid, water for
injections and liquefied nitrogen.
What Phenylephrine Injection looks like and the contents of the pack
Phenylephrine Injection is a clear, colourless solution. It is available in 1 ml glass
ampoules, in packs containing either 6 or 10 ampoules. Not all pack sizes may be
marketed.
Marketing Authorisation Holder
Amdipharm UK Limited, Capital House, 85 King William Street, London EC4N 7BL, UK
Manufacturer responsible for release
Waymade Plc, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR.
This leaflet does not contain the complete information about your medicine. If you have
any questions or are not sure about anything, ask your doctor who has access to
additional information.
This leaflet was last revised in March 2014.

Phenylepherine Inj.
10 mg per ml
102961/LF/2
Leaflet
148 x 600 mm
Great Britain
22595232
TBC
100%
Black & Cutter
19/03/2014
12 pt
1
AMCo
CAC

REGULATORY AUTHORITY
APPROVAL CONFIRMATION
Confirmation that this artwork has been approved by
the appropriate market authority (if applicable, e.g.
MHRA, IMB, etc and that Amdipharm have license
approval to distribute this component for sale in the
relevent market.
Accept Artwork ................................................................
Reject Artwork .................................................................
Signature ..........................................................................
Name ................................................................................
Date ...................................................................................

PAGE 2 OF 2

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide